NAMI Advocacy Actions

Letter to House and Senate Appropriations Committee leadership requesting $35 million for the U.S. Centers for Disease Control and Prevention (CDC), $25 million for the National Institutes of Health and $1 million for the National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention.

Letter to Congressional leadership, urging protection of the Medicaid program from cuts or harmful changes in any budget negotiations or other legislative venue this year.

Statement urging Congress to reject adding a ‘work requirement’ policy to the Medicaid program.

Statement with patient advocacy organizations on the Alliance for Hippocratic Medicine et al v FDA et al ruling and implications for future access to FDA-approved drugs.

Letter to HHS Secretary Becerra and FDA Commissioner Califf urging the Federal Drug Administration FDA to reissue its ban of electrical stimulation devices used to treat self-injurious or aggressive behavior.

Statement in response to the ruling in the Braidwood versus Becerra case, which threatens coverage of U.S. Preventive Services Task Force recommended preventive services without cost sharing as required under the Affordable Care Act.

Letter to Senate HELP Committee leadership in response to the request for information (RFI) on the health care workforce shortage.

Letter to Members of Congress in opposition to S.184 and H.R. 277 - the Regulations from the Executive in Need of Scrutiny Act of 2023 (REINS Act).

Regulatory comments to HHS Secretary Becerra and CMS Administrator Brooks-LaSure in response to the Advancing Interoperability and Improving Prior Authorization Proposed Rule.

Statement in support of federal and state policies that ensure those who remain eligible for Medicaid and CHIP understand this process and successfully reenroll, while those who are no longer eligible transition to other forms of quality, affordable healthcare coverage.